drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Chimeric IgG1 monoclonal antibody (Remicade) that binds soluble and transmembrane TNF-α, blocking TNFR1/TNFR2 signaling and downstream NF-κB–mediated inflammation; reduces pro-inflammatory cytokines (e.g., IL-1, IL-6), macrophage activation, and matrix metalloproteinases.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, neutralizing TNF-α and blocking TNFR1/TNFR2 signaling, thereby suppressing NF-κB–mediated inflammatory pathways and reducing downstream pro‑inflammatory cytokines and tissue-destructive mediators.
drug_name
Infliximab
nct_id_drug_ref
NCT02638701